ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1746

Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies

Tineke van Wesemael1, Anna Svärd2, Annemarie Dorjee1, Thomas Huizinga1, René Toes1 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Centre for Clinical Research Dalarna, Uppsala, Sweden

Meeting: ACR Convergence 2023

Keywords: Anti-CCP, Autoantibody(ies), rheumatoid arthritis, risk factors, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is the most important environmental risk factor in autoantibody-positive RA and has been described to be specifically associated with AMPA-IgG. However, although smoking exerts its effect in the lungs, it is unknown whether smoking is preferentially associated with specific autoantibody isotypes, such as IgA, which would suggest a mucosal origin. Therefore, we set out to investigate if smoking is associated with AMPA of the IgA isotype in RA.

Methods: 618 RA patients from the Leiden Early Arthritis Cohort, of whom data were available on the presence of ACPA and AAPA -IgG and -IgA, and smoking were included. Current versus ever smoking data were collected at baseline using a questionnaire. The association between smoking and autoantibodies was assessed by logistic regression analysis. Next, a meta-analyses on results from systemic literature review on the association of smoking with ACPA-IgG and ACPA-IgA was performed.

Results: In univariate analysis, smoking was associated with various autoantibodies of different isotypes (ACPA-IgG, ACPA-IgA, AAPA-IgA, RF-IgM and RF-IgA), but since isotypes often co-occur, this precluded firm conclusions. Upon examining the exact autoantibody isotype composition, smoking was only associated with AMPA-positive RA in double-positive patients, i.e. patients who harbored both IgG ánd IgA-AMPA (figure 1A and 1B). Since smoking is also associated with autoantibody levels, we then corrected the isotype-smoking associations for these levels. Strikingly, after correction for IgA, the association between AMPA-IgG and smoking was lost (Figure 1C and 1D). However, after correction for IgG, AMPA-IgA were still associated with smoking (Figure 1C and 1D).Next, a meta-analysis was performed of all publications investigating the association of smoking with ACPA-IgG and ACPA-IgA and the current data. This confirmed that smoking was associated with ACPA-IgA but not with ACPA-IgG (figure 2). Interaction analysis of shared epitope and smoking revealed that interaction was only seen in patients that were ACPA-IgG and ACPA-IgA positive, but not in patients that were only positive for ACPA-IgG (figure 3A and 3B). This indicates that the presence of ACPA-IgA is necessary for the interaction effect.

Conclusion: In RA, smoking is exclusively associated with IgA autoantibodies against post-translationally modified proteins (AMPA), and not with AMPA IgG (figure 3C). Interaction between shared epitope and smoking is also solely found in patients positive for both IgG and IgA-ACPA. These findings support the hypothesis that smoking may exert its effect by the induction of local (auto)immune responses at mucosal sites.

Supporting image 1

Figure 1. Association of smoking with anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). A. Association of smoking with ACPA IgA & ACPA IgG. B Association of smoking with AAPA IgA & AAPA IgG. C. Association of smoking with ACPA IgA and ACPA IgG corrected for respectively ACPA IgG levels and ACPA IgA levels D. Association of smoking with AAPA IgA and AAPA IgG corrected for respectively AAPA IgG positivity and AAPA IgA positivity

Supporting image 2

Figure 2. Meta-analysis for the association of smoking with anti-citrullinated protein antibodies (ACPA) IgG and ACPA IgA A. Meta-analysis for the association of smoking: ACPA IgG- ACPA IgA- versus ACPA IgG+ ACPA IgA- B. Association of smoking: ACPA IgG- ACPA IgA- versus ACPA IgG- ACPA IgA+ (no meta-analysis possible since this was examined in one study) C Meta-analysis for the association of smoking: ACPA IgG- ACPA IgA- versus ACPA IgG+ ACPA IgA+ D Meta-analysis for the association of smoking: ACPA IgG+ ACPA IgA- versus ACPA IgG+ ACPA IgA+

Supporting image 3

Figure 3. Interaction of shared epitiope (SE) and smoking with ACPA A. Interaction of smoking and SE in ACPA IgG+IGA- versus ACPA IgG-IgA- patients B. Interaction of smoking and SE in ACPA IgG+IGA+ versus ACPA IgG-IgA- patients. C. schematic representation of the association of smoking with autoantibodies in rheumatoid arthritis.


Disclosures: T. van Wesemael: None; A. Svärd: None; A. Dorjee: None; T. Huizinga: None; R. Toes: Bristol-Myers Squibb(BMS), 5; D. van der Woude: None.

To cite this abstract in AMA style:

van Wesemael T, Svärd A, Dorjee A, Huizinga T, Toes R, van der Woude D. Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/smoking-as-a-risk-factor-for-rheumatoid-arthritis-exclusive-association-with-iga-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-as-a-risk-factor-for-rheumatoid-arthritis-exclusive-association-with-iga-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology